Article Text

PDF
AB0625 Effect of one cycle of rituximab in the lipid profile of patients with refractory systemic lupus erythematosus (SLE)
  1. L. Nieves-Martín1,
  2. J.M. Pego2,
  3. J.L. Marenco3,
  4. L. Carreño4,
  5. M. Galindo5,
  6. E. Tomero6,
  7. I. Rúa-Figueroa7,
  8. B.E. Hernández8,
  9. J. Narváez9,
  10. E. Úcar10,
  11. A. Olivé11,
  12. A. Zea12,
  13. M. Fernández-Castro13,
  14. E. Raya-Άlvarez14,
  15. M. Freire15,
  16. V.M. Martínez-Taboada16,
  17. J. Pérez-Venegas17,
  18. A.I. Sánchez-Atrio18,
  19. I. Villa19,
  20. S. Manrique-Arija1,
  21. V. Rodríguez-García1,
  22. C. Romero-Barco1,
  23. F.J. Lόpez-Longo4,
  24. P.E. Carreira5,
  25. R. Martínez Pérez3,
  26. R. García-Vicuña6,
  27. A. Fernández-Nebro1
  1. 1Rheumatology service, Hospital Carlos Haya, Malaga
  2. 2Hospital do Meixoeiro, Vigo
  3. 3Hospital Virgen de Valme, Sevilla
  4. 4Hospital Gregorio Marañόn
  5. 5Hospital Doce de Octubre
  6. 6Hospital de la Princesa, Madrid
  7. 7Hospital Dr. Negrín, Gran Canaria
  8. 8Hospital Virgen Macarena, Sevilla
  9. 9Hospital de Bellvitge, Barcelona
  10. 10Hospital de Basurto, Bilbao
  11. 11Hospital Germans Trias i Pujol, Badalona
  12. 12Hospital Ramόn y Cajal
  13. 13Hospital Puerta de Hierro, Madrid
  14. 14Hospital San Cecilio, Granada
  15. 15Hospital Juan Canalejo, A Coruña
  16. 16Hospital Marqués de Valdecilla, Santander
  17. 17Hospital de Jerez de la Frontera, Jerez de la Frontera
  18. 18Hospital Príncipe de Asturias, Alcalá de Henares
  19. 19Hospital de Sierrallana, Torrelavega, Spain

Abstract

Objectives To investigate lipidic changes that occurs with Rituximab(RTX) in refractory SLE-patients.

Methods Multicenter, retrospective, longitudinal study. All SLE-patients from LESIMAB study with basic lipid data at baseline and 6±3 months after the first cycle of RTX were included. Cardiovascular risk factors (CVRF), comorbidities and treatments were collected, including lipid profile.

Results 101 patients were included (91% women; age 38.7±12.1yrs). The duration of SLE was 7.1±6.1yrs, median of severe organ-systems affected was 2.0 (range, 0-6), and median of previous drugs against SLE was 5 (range, 2-9). The Charlson-age comorbidity index was of 2.0±1.2 and the number of classic CVRF was 1.1±0.1. The baseline SLEDAI was 14.2±9.6. RTX was administrated with other drugs, including corticosteroids (n=101), hydroxychloroquine (HCQ; n=48), and statins (n=16). As it shows the table, the mean of lipid profile at baseline was good and these values were similar between patients with concomitant HCQ. The patients who were receiving statins had worse baseline lipid profile (CT, p=0.028; LDL, p=0.011; VLDL, p=0.040; TG, p=0.040).After 6±3 months of RTX treatment, the global lipids values didn’t change significantly (Table). However, the patients who achieved a good clinical response (partial or complete) in the SLE activity their lipid profile also improved [TC (p=0.004), HDL (p=0.004), VLDL (p=0.041) and TG (p=0.041)] and a correlation between improvement of SLEDAI (delta-SLEDAI at 24w from baseline, 9.8±9.5) and the improvement of the lipid profile after 24w was observed: delta-CT 24w (r=0,349; p<0,001), delta-TG 24w (r=0,366; p<0,001) y delta-VLDL 24w (r=0,366; p<0,001). Although the needs of corticosteroids decreased (delta-prednisone after 24w was 21.0±63.8mg/d), it didn’t influence in the lipid improvement, since there was no correlation between delta-prednisone after 24w and improvement in lipid profile.

Conclusions RTX doesn’t seem to have an intrinsic effect in the lipid profile from patients with refractory SLE. However, a good control of the disease activity promotes a improvement in lipid profile.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.